Drugmaker Pfizer’s 3Q profit drops 14 per cent as generic Lipitor competitors slash revenue

NEW YORK, N.Y. – Drug giant Pfizer Inc. says its third-quarter profit fell 14 per cent as sales plunged, mainly due to U.S. generic competition to cholesterol fighter Lipitor, long the world’s top-selling drug.

The maker of pain reliever Lyrica says net income was $3.21 billion, or 43 cents per share. That was down from $3.74 billion, or 48 cents per share, a year earlier.

Excluding one-time items, earnings were 53 cents per share. Analysts expected 52 cents.

Revenue fell 16 per cent to $13.98 billion, below expectations for $14.66 billion.

Pfizer raised its 2012 profit forecast, to $1.30 to $1.38 per share, from $1.21 to $1.36 per share, but reduced the top end of its revenue forecast by $1 billion.

Pfizer’s stock fell 52 cents, or 2.1 per cent, to $24.35 in premarket trading.

News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

The Associated Press

The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world’s population sees AP journalism every day.